Related Experiment Video
Updated: May 24, 2026

Technical Applications of Microelectrode Array and Patch Clamp Recordings on Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes
Published on: August 4, 2022
Application of human stem cell-derived cardiomyocytes in safety pharmacology requires caution beyond hERG
Malin K B Jonsson1, Marc A Vos, Gary R Mirams
1Department of Medical Physiology, Division Heart & Lungs, University Medical Center Utrecht, Utrecht, The Netherlands. m.k.b.jonsson@umcutrecht.nl
Insights
Human embryonic stem cell-derived cardiomyocytes (hESC-CM) show immature electrophysiology, limiting their use in safety pharmacology. Maturation is needed for accurate pro-arrhythmic trigger testing, except for hERG channel blockade.
Area of Science:
- Cardiology
- Stem Cell Biology
- Pharmacology
Background:
- Human embryonic stem cell-derived cardiomyocytes (hESC-CM) are a potential model for safety pharmacology.
- Their electrophysiological properties and pro-arrhythmic potential require thorough investigation.
Purpose of the Study:
- To evaluate the electrophysiology of hESC-CM.
- To assess their response to pro-arrhythmic drug challenges.
- To understand their suitability as a model for safety pharmacology.
Main Methods:
- Voltage patch clamp to measure ion current densities.
- Assessment of action potential parameters and early afterdepolarizations (EADs).
- Computer simulations and AP clamp analysis.
Main Results:
- hESC-CM exhibit specific ion current densities, with low I(K1) and larger I(f) compared to adult cardiomyocytes.
- Chromanol293B and Bay K8644 prolonged APD(90); Cisapride triggered EADs.
- Immature action potential in hESC-CM limits responses to pro-arrhythmic triggers, except for hERG block.
Conclusions:
- hESC-CM possess an immature electrophysiological phenotype due to low I(K1) and shifted I(Na) channel activation.
- This immaturity restricts their utility in safety pharmacology, particularly for non-hERG-related pro-arrhythmic triggers.
- Electrical phenotype maturation is essential for implementing hESC-CM in arrhythmogenic safety testing.
Abstract:
Human embryonic stem cell-derived cardiomyocytes (hESC-CM) have been proposed as a new model for safety pharmacology. So far, a thorough description of their basic electrophysiology and extensive testing, and mechanistic explanations, of their overall pro-arrhythmic ability is lacking. Under standardized conditions, we have evaluated the sensitivity of hESC-CM to proarrhythmic provocations by blockade of hERG and other channels. Using voltage patch clamp, some ion current densities (pA/pF) in hESC-CM were comparable to adult CM: I(Kr) (-12.5 ± 6.9), I(Ks) (0.65 ± 0.12), I(Na,peak) (-72 ± 21), I(Na,late) (-1.10 ± 0.36), and I(Ca,L) (-4.3 ± 0.6). I(f) density was larger (-10 ± 1.1) and I(K1) not existent or very small (-2.67 ± 0.3). The low I(K1) density was corroborated by low KCNJ2 mRNA levels. Effects of pro-arrhythmic compounds on action potential (AP) parameters and provocation of early afterdepolarizations (EADs) revealed that Chromanol293B (100 μmol/l) and Bay K8644 (1 μmol/l) both significantly prolonged APD(90). ATX-II (<1 μmol/l ) and BaCl(2) (10 μmol/l ) had no effect on APD. The only compound that triggered EADs was hERG blocker Cisapride. Computer simulations and AP clamp showed that the immature AP of hESC-CM prevents proper functioning of I(Na)-channels, and result in lower peak/maximal currents of several other channels, compared to the adult situation. Lack of functional I(K1) channels and shifted I(Na) channel activation cause a rather immature electrophysiological phenotype in hESC-CM, and thereby limits the potential of this model to respond accurately to pro-arrhythmic triggers other than hERG block. Maturation of the electrical phenotype is a prerequiste for future implementation of the model in arrhythmogenic safety testing.
More Related Videos
08:03Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation
Published on: October 20, 2022
14:03High-Throughput Cardiotoxicity Screening Using Mature Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Monolayers
Published on: March 24, 2023